Drug Repurposing for Neurodegenerative Diseases

Drug Repurposing for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Drug Repurposing for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Advantage</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Known Safety</td>
<td>Extensive clinical use data</td>
</tr>
<tr>
<td class="label">Known PK/PD</td>
<td>Established dosing</td>
</tr>
<tr>
<td class="label">Manufacturing</td>
<td>Existing production</td>
</tr>
<tr>
<td class="label">Regulatory</td>
<td>Established pathways</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Type 2 diabetes</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>AMPK activation, [mTOR](/entities/mtor) inhibition</td>
</tr>
<tr>
<td class="label">Neuroprotective Effects</td>
<td>[Autophagy](/entities/autophagy), mitochondrial biogenesis</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Type 2 diabetes</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>[GLP-1 receptor](/entities/glp1-receptor) activation</td>
</tr>
<tr>
<td class="label">CNS Effects</td>
<td>Neuroprotection, reduced neuroinflammation</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Hypercholesterolemia</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>HMG-CoA reductase inhibition</td>
</tr>
<tr>
<td class="label">Neuroprotective Effects</td>
<td>Anti-inflammatory, memb

Drug Repurposing for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Drug Repurposing for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Advantage</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Known Safety</td>
<td>Extensive clinical use data</td>
</tr>
<tr>
<td class="label">Known PK/PD</td>
<td>Established dosing</td>
</tr>
<tr>
<td class="label">Manufacturing</td>
<td>Existing production</td>
</tr>
<tr>
<td class="label">Regulatory</td>
<td>Established pathways</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Type 2 diabetes</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>AMPK activation, [mTOR](/entities/mtor) inhibition</td>
</tr>
<tr>
<td class="label">Neuroprotective Effects</td>
<td>[Autophagy](/entities/autophagy), mitochondrial biogenesis</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Type 2 diabetes</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>[GLP-1 receptor](/entities/glp1-receptor) activation</td>
</tr>
<tr>
<td class="label">CNS Effects</td>
<td>Neuroprotection, reduced neuroinflammation</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Hypercholesterolemia</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>HMG-CoA reductase inhibition</td>
</tr>
<tr>
<td class="label">Neuroprotective Effects</td>
<td>Anti-inflammatory, membrane effects</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Hypertension</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Calcium channel blocker</td>
</tr>
<tr>
<td class="label">Neuroprotective Effects</td>
<td>Calcium homeostasis</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Original Target</td>
</tr>
<tr>
<td class="label">Nilotinib</td>
<td>BCR-ABL, c-KIT</td>
</tr>
<tr>
<td class="label">Bosutinib</td>
<td>BCR-ABL</td>
</tr>
<tr>
<td class="label">Dasatinib</td>
<td>BCR-ABL</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Original Indication</td>
</tr>
<tr>
<td class="label">Sirolimus</td>
<td>Transplant rejection</td>
</tr>
<tr>
<td class="label">Everolimus</td>
<td>Cancer, tuberous sclerosis</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Bacterial infections</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Anti-inflammatory, microglial modulation</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Original Indication</td>
</tr>
<tr>
<td class="label">Ibuprofen</td>
<td>Pain/inflammation</td>
</tr>
<tr>
<td class="label">Naproxen</td>
<td>Pain/inflammation</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Potential Use</td>
</tr>
<tr>
<td class="label">Sertraline</td>
<td>AD, PD depression</td>
</tr>
<tr>
<td class="label">Fluoxetine</td>
<td>Neuroprotection</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Depression</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Sleep regulation, anti-[Aβ](/proteins/amyloid-beta)</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Epilepsy</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>[HDAC](/entities/hdac-enzymes) inhibition, mood stabilization</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Epilepsy</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Synaptic modulation</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Original Use</td>
</tr>
<tr>
<td class="label">Amphotericin B</td>
<td>Antifungal</td>
</tr>
<tr>
<td class="label">Atovaquone</td>
<td>Antiprotozoal</td>
</tr>
<tr>
<td class="label">Mebendazole</td>
<td>Anti-parasitic</td>
</tr>
<tr>
<td class="label">Doxycycline</td>
<td>Antibiotic</td>
</tr>
<tr>
<td class="label">Method</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Gene Expression</td>
<td>Connective Alchemy 基于表达谱</td>
</tr>
<tr>
<td class="label">Network Analysis</td>
<td>Protein-protein interaction networks</td>
</tr>
<tr>
<td class="label">Signature Matching</td>
<td>Compare disease and drug signatures</td>
</tr>
<tr>
<td class="label">Platform</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Connectivity Map</td>
<td>Gene expression matching</td>
</tr>
<tr>
<td class="label">Repurpose</td>
<td>Open-source drug database</td>
</tr>
<tr>
<td class="label">DrugBank</td>
<td>Computational screening</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Original Indication</td>
</tr>
<tr>
<td class="label">Liraglutide</td>
<td>Diabetes</td>
</tr>
<tr>
<td class="label">Semaglutide</td>
<td>Diabetes</td>
</tr>
<tr>
<td class="label">Dapagliflozin</td>
<td>Diabetes</td>
</tr>
<tr>
<td class="label">Atovaquone</td>
<td>Malaria</td>
</tr>
<tr>
<td class="label">Nilotinib</td>
<td>CML</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Metformin + Lifestyle</td>
<td>Metabolic + behavioral</td>
</tr>
<tr>
<td class="label">GLP-1 + Exercise</td>
<td>Synergistic effects</td>
</tr>
<tr>
<td class="label">Senolytic combination</td>
<td>Enhanced clearance</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Hypercholesterolemia</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>HMG-CoA reductase inhibition, anti-inflammatory</td>
</tr>
<tr>
<td class="label">Neuroprotective Effects</td>
<td>Reduced neuroinflammation, improved cerebral blood flow</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Hypertension, anxiety</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Beta-adrenergic receptor blockade</td>
</tr>
<tr>
<td class="label">CNS Effects</td>
<td>Reduced stress response, neuroprotection</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Chronic myeloid leukemia (dasatinib), CML (nilotinib)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>BCR-ABL inhibition, autophagy induction</td>
</tr>
<tr>
<td class="label">Neuroprotective Effects</td>
<td>Enhanced [alpha-synuclein](/proteins/alpha-synuclein) clearance, neuroprotection</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Dasatinib + Quercetin</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Autophagy induction via multiple pathways</td>
</tr>
<tr>
<td class="label">Neuroprotective Effects</td>
<td>Synergistic protein clearance</td>
</tr>
<tr>
<td class="label">Original Indication</td>
<td>Antibacterial (tetracycline)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Microglial activation modulation, anti-inflammatory</td>
</tr>
<tr>
<td class="label">CNS Effects</td>
<td>Reduced neuroinflammation</td>
</tr>
</table>

Drug Repurposing For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Drug repurposing (also called drug repositioning) involves identifying new therapeutic uses for existing drugs that were developed for other conditions. This approach offers significant advantages: established safety profiles, known pharmacokinetics, reduced development time, and lower costs [@ashburn2004]. [@campbell2018]

Advantages of Repurposing

Repurposed Drugs in Neurodegeneration

Diabetes Drugs

Metformin

Clinical Evidence:

• Reduced dementia risk in diabetics (retrospective)
• Ongoing trials in MCI/AD (NCT04098627)
• Potential disease-modifying effects [@campbell2018]

GLP-1 Agonists (Exenatide, Liraglutide, Semaglutide)

Clinical Evidence:

• Exenatide: Motor improvement in PD (Phase 2)
• Liraglutide: Cognitive benefit in AD (Phase 2)
• Semaglutide: Trials in AD (Phase 3)
• Neuroprotective in preclinical models [@athauda2017]

Cardiovascular Drugs

Statins

Clinical Evidence:

• Mixed results in AD prevention
• Possible benefit in PD
• Ongoing trials for safety signals

Amlodipine

Clinical Evidence:

• Reduced AD risk in some studies
• Trial in PD (NCT05148806)
• [BBB](/entities/blood-brain-barrier)-penetrating statin use studied

Anti-Cancer Drugs

Tyrosine Kinase Inhibitors

Clinical Evidence:

• Nilotinib: Phase 2 in PD showed motor improvement
• Dasatinib + Quercetin: Senolytic trial in AD
• Ongoing trials in PD and AD [@pagan2022]

mTOR Inhibitors

Clinical Evidence:

• Sirolimus: Improved cognition in AD mouse models
• Everolimus: Trials in TSC-related CNS issues

Anti-Inflammatory Drugs

Minocycline

Clinical Evidence:

• Failed in ALS (Phase 3)
• No benefit in AD
• Preclinical neuroprotection not replicated

NSAIDs

Clinical Evidence:

• Observational studies suggested benefit
• Prospective trials negative
• Timing may be critical

Antidepressants

SSRIs

Clinical Evidence:

• Sertraline: Cognitive benefit in depression
• Fluoxetine: Motor improvement in PD models

Trazodone

Clinical Evidence:

• Sleep benefits in neurodegeneration
• Preclinical [Aβ](/proteins/amyloid-beta) reduction
• Trial in AD (NCT03042261)

Anti-Epileptic Drugs

Valproic Acid

Clinical Evidence:

• Failed in AD
• Mood benefits in PD
• Liver toxicity concerns

Levetiracetam

Clinical Evidence:

• Reduced network hyperexcitability
• Cognitive benefits in studies
• SV2A modulation

Other Repurposed Agents

High-Throughput Screening Approaches

Bioinformatic Prediction

Drug-Disease Matching

Clinical Trial Landscape

Active Repurposing Trials

Challenges and Limitations

Efficacy Limitations

• Modest effect sizes in many cases
• Optimal dosing unclear for CNS
• Disease-specific considerations

Safety Concerns

• Long-term safety in elderly
• Drug-drug interactions
• Pre-existing conditions

Regulatory Challenges

• Patent protection issues
• Reformulation needs
• Development costs despite advantages

Future Directions

Combination Repurposing

Precision Repurposing

• Genetic subtypes informing drug selection
• Biomarker-guided approaches
• Patient stratification

See Also

• [GLP-1 Receptor Agonists for Neurodegeneration](/therapeutics/glp-1-receptor-agonists-neurodegeneration)
• [Exenatide for Parkinson's Disease](/therapeutics/exenatide-parkinsons-disease)
• [Drug Development Pipeline](/therapeutics/)
• [Alzheimer's Disease Treatments](/therapeutics/)

External Links

• [ClinicalTrials.gov - Drug Repurposing](https://clinicaltrials.gov/search?cond=neurodegenerative&intr=repurpos)
• [DrugBank](https://go.drugbank.com/)
• [Repurpose](https://www.repurpose.io/)

Background

The study of Drug Repurposing For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Cardiovascular Drugs

Statins (Atorvastatin, Simvastatin)

Clinical Evidence:

• Observational studies show reduced dementia risk with statin use
• Ongoing trials in AD (NCT02728856)
• Potential for vascular dementia prevention

Beta-Blockers (Propranolol)

Clinical Evidence:

• Observational studies link beta-blocker use to reduced AD risk
• Phase 2 trial in AD-related agitation (NCT03116156)

Anti-Cancer Drugs

Tyrosine Kinase Inhibitors (Dasatinib, Nilotinib)

Clinical Evidence:

• Dasatinib: FDA-approved for CML, trials in PD (Phase 1/2)
• Nilotinib: Shows promise in PD/AD trials
• Low-dose treatment may reduce toxic protein aggregates

Metformin + Dasatinib Combination

Clinical Evidence:

• D+Q (Senolytics): Eliminates senescent cells
• Trials in AD, PD, and aging (NCT04685590)

Anti-Inflammatory Drugs

Microglial Modulators (Minocycline)

Clinical Evidence:

• Mixed results in ALS and AD trials
• Early intervention may be key

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
• [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF
• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2

Related Analyses:

• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;